Vanderbilt TB Center News

WHO Global TB Report was released!

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

New RePORT-Brazil publication: The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study!

The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study was generated from the RePORT-Brazil collaboration, led by Maria Arriaga, and published in The Journal of Infectious Diseases Background: It is unclear whether diabetes or prediabetes affect unfavorable treatment outcomes and death in people with tuberculosis (PWTB).

Welcome Rebecca “Ribka” Berhanu, MD, as a new Assistant Professor in the Division of Infectious Disease!

Dr. Berhanu is an infectious diseases physician and clinical researcher. She is originally from Addis Ababa, Ethiopia. She completed her undergraduate degree at Stanford University and her medical degree at the Baylor College of Medicine. Ribka did her clinical training in internal medicine at the University of Chicago and her fellowship in infectious diseases at the University of North Carolina. She subsequently completed a post-doctoral fellowship at the Boston University School of Public Health. 

New RePORT-Brazil publication: Determinants of losses in the latent tuberculosis infection cascade of care in Brazil

Determinants of losses in the latent tuberculosis infection cascade of care in Brazil publication was generated from the RePORT-Brazil collaboration, and published in BMJ Global Health Introduction: Factors associated with losses in the latent tuberculosis infection (LTBI) cascade of care in contacts of patients with tuberculosis (TB) were investigated in a multicentre prospective cohort from highly endemic regions in Brazil.

Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.